Meet our partners
Global Partner
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. Read more at

Mar 2016 MedImmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A

Feb 2016 AstraZeneca funds 'robotic pill' company Rani Therapeutics in pursuit of oral biologics

Dec 2015 AstraZeneca buys majority stake in blood cancer specialist Acerta for £2.68bn

OneStart Europe Vision Film 2016

  • Lynne Murray, Partnering and Strategy, MedImmune/AstraZeneca
  • Dan Perez, CEO & Founder, Oxbridge Biotech Roundtable 
  • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
  • Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson 
  • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC
  • Matthew Foy, Partner, SR One
  • Sarah Haywood, CEO, MedCity 
  • Matthias Essenpreis, CTO (Diagnostics), F-Hoffman-La Roche Ltd. 
  • Rachel Moss, Associate Principal, McKinsey and Company 
  • Claire Brown, Investment Manager, Alderley Park Ventures / BioCity 
  • Aric Orbach, Head of Pharmacology, Teva Pharmaceutical Industries 
  • Stephen Reese, Partner, Olswang LLP 
  • Ilan Zipkin, Investment Director, Takeda Ventures Inc. 

    From the OneStart London Bootcamp 2016 

    Panel Discussion

    Panel Discussion: Health Economics and Understanding Payers

  • Sarah Haywood, COO, MedCity (Chair)
  • James Ryan, Global Director of HERO, AstraZeneca
  • Elangovan Gajraj, Technical Advisor, NICE
  • Sandiatu Dixon-Fyle, PhD, Senior Healthcare Expert, McKinsey & Company
  • Anna King, Commercial Director, Health Innovation, Network

  • Panel Discussion: Navigating Critical Decision Points

    • Lynne Murray, PhD, MBA, Partnering & Strategy, MedImmune (Chair)
    • Matthias Essenpreis, PhD, Chief Technology Officer (Diagnostics), F.Hoffmann-La Roche Ltd.
    • Georg Buchner, PhD MBA, Licensing Director, Amgen 
    • Sarah Holland, DPhil (Oxon), MBA, External Science and Partnering, Sanofi
    • Jonathan Tobin, PhD, MBA, Principal, Healthcare Venture, Imperial Innovations

    From the OneStart San Francisco Bootcamp 2016

    Panel Discussion

    Panel Discussion: Accessing and Interacting with Industry
    • Thomas Luby, PhD, Senior Director of New Ventures, Johnson & Johnson innovation, Boston (Chair)
    • Sam Wu, Managing Director, MedImmune Ventures 
    • Lucy Perez, PhD, Partner, McKinsey and Company
    • Sharon Cload, VP Molecular Discovery Technologies, Bristol-Myers Squibb
    • David Wilson, PhD, VP Biologics, Teva Pharmaceuticals
    A. Maria Dahl
    Executive Business Development Director, AstraZeneca + more
    My responsibilities are for negotiating oncology licensing and collaboration agreements. I have more than 12 years experience in business development and portfolio management from the US and UK pharmaceutical and biotech industry. I have also been a non-executive director on the board of a private UK biotech company, and also previously co-chaired or been a jury member in US and French business plan competitions.
    Simon Hollingsworth
    Executive Director, Oncology Innovative Medicines & Early Development, AstraZeneca + more
    I'm responsible for development and delivery of AstraZeneca’s portfolio of Stratified Medicine Studies, partnered Stratified Medicine initiatives (National, European, US, Asia) and basket studies, and Senior Project Director in Oncology Early Clinical Development. I have >20 years experience in drug and therapeutics development across industry (AstraZeneca, Roche/Genentech) and academic (University College London, King’s College London) careers focused in clinical and translational science, and personalised healthcare in oncology, inflammation and cardio-/vascular fields.
    Lynne Murray
    Associate Director, Partnering & Strategy, MedImmune + more
    After joining MedImmune, I initially focused on the fibrosis research efforts, both internally and with external collaborators and have since gained an MBA. I'm now Partnering & Strategy group at MedImmune and my research interests span the underlying pathways promoting the effects of injury, inflammation and I have successfully transitioned 3 therapeutics into Ph2.
    Adam McNulty
    Scientific Partnering and Alliances, AstraZeneca + more
    Scientific Partnering and Alliances supporting the Oncology iMED and the Emerging Innovations Unit (EIU), a virtualized, externally focused R&D team. This includes negotiation and execution of any and all agreements related to early stage small molecule oncology assets and the out licensing of phase 2b ready EIU assets.
    Duncan Young
    Academic Alliances Manager, Scientific Partnering & Alliances, AstraZeneca + more
    Experienced Business Development professional with keen interest in new models of collaborative working and open innovation between academia, the charity sector and industry. Specialities: Open Innovation, Drug Discovery, Medical Technologies, Technology Transfer, IP Management, Technical Due Diligence and Evaluation, Networking, Agreement Negotiation, Consortia Drafting
    Paolo Vicini
    Senior Director at MedImmune + more
    Head of the Medlmmune Cambridge department of Clinical Pharmacology and DMPK (CPD), one of three global Medlmmune sites providing PKPD, pharmacometrics and bioanalytical support for the biotherapeutic products pipeline. Responsible for establishing strategy, direction, and objectives for the CPD site, and ensuring progress towards objectives. Accountable for all aspects of CPD for products at discovery, nonclinical and clinical stages of development Collaborate with bioanalytical and translational CPD scientists on the development, validation, and conduct of PK, immunogenicity, and biomarker assays. Active contributor to R&D and corporate governance committees and the strategic direction of the broader research organization, including harmonization between sites.
    Louise Fairburn
    Vice President. Global Commercial Learning Academy at AstraZeneca + more
    A global pharmaceutical business leader experienced in marketing, sales, commercial operations and corporate affairs. Demonstrated ability and track record of building, leading and motivating large cross-functional teams across geographical boundaries and cultures. Demonstrated ability to lead innovation and change in large organisations and teams. More than 22 years experience in the pharmaceutical industry with more than 10 years in senior roles
    Samantha Macro
    Head of Finance, Medimmune + more
    Head of Finance - Medimmune Cambridge (formerly Cambridge Antibody Technology)
    Teams Mentored